Heliospectra AB Announcing CORTEX

“”

The Market’s Leading Control Software for Consistent, High-Quality Crop Production Year-Round (GOTHENBURG, Sweden / SAN FRANCISCO, CA, June 14, 2017) – Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, introduces CORTEX – the market’s leading light control software. The new Heliospectra solution enables growers to significantly increase consistency and control of crop quality, harvest cycles and yields.

Heliospectra AB introducerar CORTEX

“”

Marknadens ledande kontrollsystem för standardiserad, högkvalitativ produktion av grödor  Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), världsledande inom intelligent belysningsteknik för växthus och kontrollerade odlingsmiljöer, introducerar CORTEX – marknadens ledande kontrollsystem för växtbelysning. Heliospectras nya system ger odlare ökad kontroll och möjliggör standardisering av grödans kvalitet, skördecykler och avkastning.

Mak North America Place Second Order of Heliospectra Intelligent LED Technology

Macedonia’s First Licensed Cannabis Cultivation Facility Scales Lighting Solutions with Focus on Controlling Consistency for Business Growth and Medicinal Product Quality (GOTHENBURG, Sweden / SAN FRANCISCO, CA, June 8, 2017) – Heliospectra AB  (https://www.heliospectra.com/)(publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, announced a second order from Mak North America of Heliospectra LED lighting solutions as the company opens the first licensed medicinal cannabis cultivation facility in the Republic of Macedonia. The order value is USD 184,560 (1,5 million SEK). Delivery will take place at the beginning of Q3 and be visible in the accounts in Q2 and Q3.

Mak North America lägger ny order på Heliospectras intelligenta LED belysning

Makedoniens första licenserade cannabisodling lägger fokus på standardisering för ökad tillväxt och produktkvalitet med hjälp av intelligent LED belysning Heliospectra AB (publ), världsledande inom intelligent ljusteknik för kontrollerad miljö, växtforskning och växthusodling, meddelade idag att Mak North America har lagt en andra order av Heliospectras LED-belysningslösningar till ett ordervärde av 1,5 miljoner kr (USD 184 560). Lamporna kommer att användas i den första licensierade medicinska odlingsanläggningen för cannabis i Makedonien. Leverans är beräknad till början av Q3 och kommer att synas i räkenskaperna under Q2 samt Q3.

Heliospectra AB to Present at Upcoming Session of Viridian Cannabis Investment Series in New York City

(GOTHENBURG, SWEDEN and SAN FRANCISCO, CA – March 27, 2017) – Heliospectra AB (https://www.heliospectra.com/) (OTCQB: HLSPY (http://www.otcmarkets.com/stock/HLSPY/quote)) (FIRSTNORTH: HELIO (http://www.nasdaqomxnordic.com/shares/microsite?Instrument=SSE101607&symbol=HELIO&name=Heliospectra)), a world leader in intelligent lighting technology for controlled plant growth environments , announced today that CEO Ali Ahmadian will present at the upcoming session of the Viridian Cannabis Investment Series (http://www.viridianca.com/viridian-cannabis-investment-series-new-york-2017/) at the John Jay College of Criminal Justice in New York City, New York on Friday, March 31, 2017.

Canada’s Island Garden Inc. Enhances Production with Heliospectra Intelligent Lighting Solution

(GOTHENBURG, Sweden / SAN FRANCISCO, CA, March 23, 2017) – Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for controlled plant growth environments, announced today that Canada’s Island Garden Inc, a licensed medical cannabis cultivation facility located on Prince Edward Island, Canada, decided to invest in Heliospectra intelligent LED lighting solution (https://www.heliospectra.com/led-grow-lights-applications)s at a value of $208,368 USD (1,871,186 SEK). This will be the second purchase for this customer following an extensive trial period.